Reg FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): August 23, 2023     CVS HEALTH CORPORATION (Exact name of registrant as specified in charter)           Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)   One CVS Drive Woonsocket , Rhode Island   02895 (Address of principal executive offices)   (Zip Code)         Registrant’s telephone number, including area code: ( 401 ) 765-1500 Former name or former address, if changed since last report: N/A       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share CVS New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).      Emerging growth company   o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       o               Item 7.01 Regulation FD Disclosure.   CVS Health Corporation (“CVS Health,” the “Company,” “we” or “our”) today announced that it has launched Cordavis, a wholly owned subsidiary that will work directly with manufacturers to commercialize and/or co-produce biosimilar products (an FDA approved biologic medication that is highly similar to, and has no clinically meaningful differences from, a biologic medicine already approved by the FDA) to the U.S. pharmaceutical market. Cordavis will work with manufacturers to commercialize or co-produce products under the Cordavis label. Cordavis biosimilar products will be FDA approved, high quality, and easy for patients to use and are expected to help ensure consistent long-term supply of affordable biosimilars.   A copy of the press release announcing the launch of Cordavis is furnished herewith as Exhibit 99.1 and hereby incorporated in this Item 7.01 by reference.   Cautionary Statement Concerning Forward-Looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation. Statements in this Press Release that are forward-looking include statements regarding potential savings opportunities and the expected pipeline of products. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties described in our Securities and Exchange Commission filings, including those set forth in the Risk Factors section and under the heading “Cautionary Statement Concerning Forward-Looking Statements” in our most recently filed Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K.   You are cautioned not to place undue reliance on CVS Health’s forward-looking statements. CVS Health’s forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. CVS Health does not assume any duty to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise.   Section 9 - Financial Statements and Exhibits   Item 9.01 Financial Statements and Exhibits.   (d)         Exhibits .   The exhibits to this Current Report on Form 8-K are as follows:   INDEX TO EXHIBITS   Exhibit Description     99.1 Press Release of CVS Health Corporation dated August 23, 2023     104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.                       SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.         CVS HEALTH CORPORATION   Dated:  August 23, 2023           By: /s/ Colleen M. McIntosh       Colleen M. McIntosh Senior Vice President, Secretary and Chief Governance Officer